C&W nets AstraZeneca prostate cancer job

AstraZeneca is to overhaul the PR strategy for its two top-selling hormonal therapies for prostate cancer treatment.

Cohn & Wolfe has beaten Hill & Knowlton and four-year incumbent Burson-Marsteller to scoop an international contract to promote the Casodex and Zoladex brands.

C&W will implement a disease-awareness campaign in addition to helping AZ promote the latest clinical trial data on the products. Director Jacinta Collins leads the account.

It is understood that a decision has not yet been made as to which agency will promote the brand in the UK, where the account - held by B-M – has also been reviewed.

Mainly affecting men aged above 50, prostate cancer is the most common male cancer and is responsible for the second highest number of cancer deaths in men, exceeded only by lung cancer.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in